Enzon Pharmaceuticals, Inc. (ENZN) Research

Enzon Pharmaceuticals, Inc., along with its various subsidiaries, primarily focuses on the commercialization of pharmaceutical products. PegIntron is a key drug within its actively marketed portfolio. The company also maintains a specific marketing agreement for the medication Vicineum. Established in 1981, Enzon Pharmaceuticals is headquartered in Cranford, New Jersey.

Market snapshot

Symbol
ENZN
Price
$5.50
Day change
-1.79%
Market cap
$4.1M
P/E ratio
-4.56x
52-week range
0.02-8.55
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Core One Labs Inc. (CLABF)
  • Canntab Therapeutics Limited (CTABF)
  • Doseology Sciences Inc. (DOSEF)
  • Futura Medical plc (FAMDF)
  • Evolutionary Genomics, Inc. (FNAM)
  • HealthLynked Corp. (HLYK)
  • LFTD Partners Inc. (LIFD)
  • Sigyn Therapeutics, Inc. (SIGY)

Recent insider activity

  • Pettit Craig — trade (0 shares) on 2026-04-30
  • WILLS STEPHEN T — trade (0 shares) on 2025-01-07
  • READ RANDOLPH C — P-Purchase (84550 shares) on 2023-06-16
  • READ RANDOLPH C — P-Purchase (15000 shares) on 2023-06-14
  • Firestone Jaffrey Adam — trade (0 shares) on 2022-06-09

Open Enzon Pharmaceuticals, Inc. (ENZN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.